Natera (NASDAQ:NTRA) Shares Acquired Rep. Josh Gottheimer

Representative Josh Gottheimer (D-New Jersey) recently bought shares of Natera, Inc. (NASDAQ:NTRA). In a filing disclosed on December 05th, the Representative disclosed that they had bought between $1,001 and $15,000 in Natera stock on November 20th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Regeneron Pharmaceuticals (NASDAQ:REGN) on 11/29/2024.
• Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 11/27/2024.
• Sold $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 11/27/2024.
• Sold $1,001 – $15,000 in shares of Vertiv (NYSE:VRT) on 11/27/2024.
• Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 11/26/2024.
• Purchased $1,001 – $15,000 in shares of Dominion Energy (NYSE:D) on 11/26/2024.
• Purchased $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 11/26/2024.
• Sold $1,001 – $15,000 in shares of Eaton (NYSE:ETN) on 11/25/2024.
• Sold $1,001 – $15,000 in shares of ConocoPhillips (NYSE:COP) on 11/22/2024.
• Purchased $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 11/22/2024.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $171.65 on Friday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12-month low of $55.56 and a 12-month high of $175.63. The business has a fifty day simple moving average of $140.16 and a 200 day simple moving average of $122.43.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same period last year, the company earned ($0.95) EPS. On average, equities research analysts predict that Natera, Inc. will post -1.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Morgan Stanley raised their target price on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. JPMorgan Chase & Co. increased their price target on Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. BTIG Research increased their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Canaccord Genuity Group increased their price target on Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Robert W. Baird increased their price target on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $140.59.

Insider Buying and Selling at Natera

In related news, Director Roelof Botha sold 87,473 shares of Natera stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $169.12, for a total value of $14,793,433.76. Following the sale, the director now owns 1,224,787 shares of the company’s stock, valued at approximately $207,135,977.44. The trade was a 6.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gail Boxer Marcus sold 9,682 shares of Natera stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $159.98, for a total transaction of $1,548,926.36. Following the completion of the transaction, the director now owns 9,704 shares of the company’s stock, valued at $1,552,445.92. This represents a 49.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 133,976 shares of company stock worth $21,119,238. Insiders own 7.60% of the company’s stock.

Institutional Trading of Natera

Several large investors have recently made changes to their positions in NTRA. Farallon Capital Management LLC boosted its stake in Natera by 13.6% during the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after purchasing an additional 532,874 shares during the last quarter. Wellington Management Group LLP boosted its stake in Natera by 205.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after purchasing an additional 1,883,481 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Natera by 3.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock valued at $315,194,000 after purchasing an additional 85,236 shares during the last quarter. Geode Capital Management LLC boosted its stake in Natera by 7.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock valued at $265,747,000 after purchasing an additional 143,825 shares during the last quarter. Finally, Duquesne Family Office LLC boosted its stake in Natera by 2.4% during the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock valued at $213,860,000 after purchasing an additional 45,500 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2025. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2024 election. Gottheimer was first elected to the House in 2016. Prior to his election, Gottheimer worked for Microsoft, the Federal Communications Commission, and for the administration of President Bill Clinton (D). Click here for more information about Gottheimer’s career. Gottheimer serves on the House Financial Services Committee, where is a member of three subcommittees. For more on Gottheimer’s committee assignments, click here. Gottheimer became a co-chair of the Problem Solvers Caucus in February 2017. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.